How to optimize pharmaceutical development through extractables and leachables studies
Pharmaceutical development optimization largely depends on the ability to evaluate all factors interacting with the formulation, especially those related to packaging materials and containment systems. In this context, extractables and leachables (E&L) studies have become an essential tool to ensure the safety, stability, and quality of medicines throughout their entire shelf life.
Strategic importance of analytical studies
Extractables studies constitute the first step in understanding how materials in contact with the drug behave. By exposing plastics, elastomers, or metals to extreme conditions—such as aggressive solvents, high temperatures, or extended time periods—a complete profile of sbustances that could migrate into the formulation is obtained.
This initial information allows laboratories to anticipate potential incompatibilities and design more precise control strategies. Subsequently, leachables analyses, performed directly on the drug under real storage and usage conditions, consolidate and validate these data. Thanks to this correlation between experimental scenarios and real-world conditions, a reliable view of the potential migration risk throughout the product life cycle is achieved.
Impact of extractables and leachables studies on drug quality, stability, and safety
The presence of undesired compounds can compromise drug stability, alter its pH, generate by-products, or affect its impurity profile. Likewise, certain substances may impact microbiological integrity or trigger chemical reactions that reduce therapeutic efficacy.
For this reason, quality departments allocate significant resources to conducting extractables and leachables studies that provide reproducible, traceable results based on advanced analytical techniques.
Tools such as high-resolution chromatography, mass spectrometry, and thermal analyses enable the detection and quantification of substances at very low concentrations. This systematic approach strengthens process control and rigorously documents the absence of relevant interferences in the formulation.
Regulatory requirements and compliance
International agencies, such as the EMA, FDA, and USP, require proof that materials in contact with the product do not pose risks to patient health. To achieve this, regulatory dossiers must include studies that follow guidelines such as USP <1663>/<1664>, ICH, and material compatibility-specific regulations.
Insufficient data can lead to delays in drug approval, additional audits, or requests for supplementary information. Integrating these studies from the early stages of development avoids rework, accelerates decision-making, and ensures compliance with regulatory requirements.
Development optimization and risk reduction
Early incorporation of extractables and leachables studies allows the identification of incompatibilities before they affect design, formulation, or stability testing. This proactive approach reduces costs, minimizes risks, and promotes more efficient development.
These specialized studies not only ensure the safety of the drug but also provide competitive advantages by improving decision-making, optimizing processes, and reducing the risk of regulatory incidents.
